GlassScriptPhysician profile
Jasmine Gill
NPI 1164747697
$3,054.50
in general payments reported to CMS, 2019-2025
21 companies · $880 in 2025
The $880 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.77 · 2021: $133 · 2022: $380 · 2023: $743 · 2024: $842 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.07 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $484.36 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $325.48 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $193.04 | 2022-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $166.73 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $151.44 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $114.66 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $106.77 | 2025 | Cobenfy |
| Corium, LLC | $101.89 | 2022-2025 | Azstarys |
| Alkermes, INC. | $99.64 | 2019-2023 | Vivitrol |
| Collegium Pharmaceutical, INC. | $94.61 | 2025 | Jornay Pm |
| Lundbeck LLC | $92.79 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $79.87 | 2022-2025 | |
| Bausch Health US, LLC | $46.93 | 2022-2025 | Wellbutrin |
| Janssen Pharmaceuticals, INC | $43.98 | 2019-2024 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.16 | 2021 | |
| Indivior INC. | $30.41 | 2019 | |
| Braeburn INC. | $28.71 | 2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $25.96 | 2024 | Fanapt |
| Owp Pharmaceuticals, INC. | $18.62 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.38 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.